Press Releases

Vancouver, BC – November 23, 2017 – Exro Technologies Inc. (“Exro” or the "Company") (CSE:XRO), at the request of IIROC, wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

Exro Technologies Inc. (formerly BioDE Ventures Ltd.) (CSE: XRO) (the “Company” or “Exro”) is pleased to announce that John Meekison has been appointed as the Company’s new Chief Financial Officer (“CFO”) and that it has closed the sale of its legacy biotech assets.

Exro Technologies Inc. (formerly BioDE Ventures Ltd.) (CSE: XRO) would like to update shareholders about the Company's test facilities and collaboration initiatives.

Exro Technologies Inc. (formerly BioDE Ventures Ltd.) (the “Company”) (CSE: XRO) announces that it closed the private placement (the “Private Placement”) disclosed in the news release on August 17, 2017.

Exro announces that its common shares will be listed on the Canadian Securities Exchange commencing on Tuesday, August 29, 2017 under the trading symbol XRO.